Skip to content

13F-HR filed by Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP filed this 13F-HR for the quarter ended 2022-03-31, filed 2022-05-16, with 25 holding rows worth $378,173,000.

Accession
0001855655-22-000006
Filed
2022-05-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2022

A holdings report, 25 entries on the cover page, a total value of $378,173,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $378,175,000 with VALUE read as thousands by filing date, 13F file number 028-21950. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR321,621$37,745,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM966,827$33,491,000thousands by filing date
ARVINAS INC04335A105COM491,333$33,067,000thousands by filing date
LEGEND BIOTECH CORP52490G102SPONSORED ADS831,728$30,225,000thousands by filing date
SIERRA ONCOLOGY INC82640U404CMN771,314$24,721,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM1,256,051$23,224,000thousands by filing date
INCYTE CORP COM45337C102Stock234,419$18,618,000thousands by filing date
IVERIC BIO INC46583P102COM910,416$15,322,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM907,428$15,109,000thousands by filing date
IMMUNOCORE HLDGS PLC ADS45258D105ADR499,190$14,926,000thousands by filing date
HORIZON THERAPEUTICS PLCG46188101SHS136,243$14,334,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock75,635$13,570,000thousands by filing date
ZENTALIS PHARMACEUTICALS INC98943L107COMMON STOCK287,577$13,269,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM701,356$12,190,000thousands by filing date
C4 THERAPEUTICS INC12529R107COM STK499,496$12,118,000thousands by filing date
OYSTER POINT PHARMA INC69242L106COMMON STOCK987,698$11,497,000thousands by filing date
PROTHENA CORP PLC SHSG72800108Stock267,946$9,799,000thousands by filing date
KYMERA THERAPEUTICS INC501575104COM227,034$9,608,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM98,383$8,089,000thousands by filing date
MERUS N VN5749R100COM249,738$6,603,000thousands by filing date
VOR BIOPHARMA INC929033108COM894,404$5,402,000thousands by filing date
ESPERION THERAPEUTICS INC NEW COM29664W105Stock1,157,246$5,370,000thousands by filing date
FULCRUM THERAPEUTICS INC359616109COMMON STOCK212,961$5,037,000thousands by filing date
ALPINE IMMUNE SCIENCES INC02083G100COM336,229$3,016,000thousands by filing date
GRACELL BIOTECHNOLOGIES INC38406L103ADR783,445$1,825,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001855655-22-000006this filing2022-05-16acceptance time not in the bulk data set